http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 27 Jul 2026 05:02:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that it has entered into a strategic collaboration with <span>China National Pharmaceutical Group Co., Ltd.</span> ("Sino<span id="spanHghlt16e1">pharm</span><span id="spanHghlt57e6">"</span>). The two parties will establish the Sino<span id="spanHghlt2cda">pharm</span> - Harbour BioMed <span id="spanHghlt2b84">Innova</span>tion Consortium (the "<span id="spanHghlt0fa5">Inno</span>vation Consortium") to advance collaborative research and development of innovative biologics.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html Mon, 27 Jul 2026 05:02:00 -0400 02142 2142 6XY A.19193785 O.27286523 O.34279193 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that it has entered into a strategic collaboration with <span>China National Pharmaceutical Group Co., Ltd.</span> ("Sino<span id="spanHghlt16e1">pharm</span><span id="spanHghlt57e6">"</span>). The two parties will establish the Sino<span id="spanHghlt2cda">pharm</span> - Harbour BioMed <span id="spanHghlt2b84">Innova</span>tion Consortium (the "<span id="spanHghlt0fa5">Inno</span>vation Consortium") to advance collaborative research and development of innovative biologics.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html Mon, 27 Jul 2026 05:02:00 -0400 02142 2142 6XY A.19193785 O.27286523 O.34279193 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that it has entered into a strategic collaboration with <span>China National Pharmaceutical Group Co., Ltd.</span> ("Sino<span id="spanHghlt16e1">pharm</span><span id="spanHghlt57e6">"</span>). The two parties will establish the Sino<span id="spanHghlt2cda">pharm</span> - Harbour BioMed <span id="spanHghlt2b84">Innova</span>tion Consortium (the "<span id="spanHghlt0fa5">Inno</span>vation Consortium") to advance collaborative research and development of innovative biologics.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html Mon, 27 Jul 2026 05:02:00 -0400 02142 2142 6XY A.19193785 O.27286523 O.34279193 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that it has entered into a strategic collaboration with <span>China National Pharmaceutical Group Co., Ltd.</span> ("Sino<span id="spanHghlt16e1">pharm</span><span id="spanHghlt57e6">"</span>). The two parties will establish the Sino<span id="spanHghlt2cda">pharm</span> - Harbour BioMed <span id="spanHghlt2b84">Innova</span>tion Consortium (the "<span id="spanHghlt0fa5">Inno</span>vation Consortium") to advance collaborative research and development of innovative biologics.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html Mon, 27 Jul 2026 05:02:00 -0400 02142 2142 6XY A.19193785 O.27286523 O.34279193 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that it has entered into a strategic collaboration with <span>China National Pharmaceutical Group Co., Ltd.</span> ("Sino<span id="spanHghlt16e1">pharm</span><span id="spanHghlt57e6">"</span>). The two parties will establish the Sino<span id="spanHghlt2cda">pharm</span> - Harbour BioMed <span id="spanHghlt2b84">Innova</span>tion Consortium (the "<span id="spanHghlt0fa5">Inno</span>vation Consortium") to advance collaborative research and development of innovative biologics.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html Mon, 27 Jul 2026 05:02:00 -0400 02142 2142 6XY A.19193785 O.27286523 O.34279193 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that it has entered into a strategic collaboration with <span>China National Pharmaceutical Group Co., Ltd.</span> ("Sino<span id="spanHghlt16e1">pharm</span><span id="spanHghlt57e6">"</span>). The two parties will establish the Sino<span id="spanHghlt2cda">pharm</span> - Harbour BioMed <span id="spanHghlt2b84">Innova</span>tion Consortium (the "<span id="spanHghlt0fa5">Inno</span>vation Consortium") to advance collaborative research and development of innovative biologics.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html Mon, 27 Jul 2026 05:02:00 -0400 02142 2142 6XY A.19193785 O.27286523 O.34279193 http://www.streetinsider.com/PRNewswire/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that it has entered into a strategic collaboration with <span>China National Pharmaceutical Group Co., Ltd.</span> ("Sino<span id="spanHghlt16e1">pharm</span><span id="spanHghlt57e6">"</span>). The two parties will establish the Sino<span id="spanHghlt2cda">pharm</span> - Harbour BioMed <span id="spanHghlt2b84">Innova</span>tion Consortium (the "<span id="spanHghlt0fa5">Inno</span>vation Consortium") to advance collaborative research and development of innovative biologics.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html Mon, 27 Jul 2026 05:02:00 -0400 02142 2142 6XY A.19193785 O.27286523 O.34279193 http://www.streetinsider.com/PRNewswire/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that it has entered into a strategic collaboration with <span>China National Pharmaceutical Group Co., Ltd.</span> ("Sino<span id="spanHghlt16e1">pharm</span><span id="spanHghlt57e6">"</span>). The two parties will establish the Sino<span id="spanHghlt2cda">pharm</span> - Harbour BioMed <span id="spanHghlt2b84">Innova</span>tion Consortium (the "<span id="spanHghlt0fa5">Inno</span>vation Consortium") to advance collaborative research and development of innovative biologics.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html Mon, 27 Jul 2026 05:02:00 -0400 02142 2142 6XY A.19193785 O.27286523 O.34279193 http://www.streetinsider.com/PRNewswire/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that it has entered into a strategic collaboration with <span>China National Pharmaceutical Group Co., Ltd.</span> ("Sino<span id="spanHghlt16e1">pharm</span><span id="spanHghlt57e6">"</span>). The two parties will establish the Sino<span id="spanHghlt2cda">pharm</span> - Harbour BioMed <span id="spanHghlt2b84">Innova</span>tion Consortium (the "<span id="spanHghlt0fa5">Inno</span>vation Consortium") to advance collaborative research and development of innovative biologics.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html Mon, 27 Jul 2026 05:02:00 -0400 02142 2142 6XY A.19193785 O.27286523 O.34279193 http://www.streetinsider.com/PRNewswire/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that it has entered into a strategic collaboration with <span>China National Pharmaceutical Group Co., Ltd.</span> ("Sino<span id="spanHghlt16e1">pharm</span><span id="spanHghlt57e6">"</span>). The two parties will establish the Sino<span id="spanHghlt2cda">pharm</span> - Harbour BioMed <span id="spanHghlt2b84">Innova</span>tion Consortium (the "<span id="spanHghlt0fa5">Inno</span>vation Consortium") to advance collaborative research and development of innovative biologics.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html Mon, 27 Jul 2026 05:02:00 -0400 02142 2142 6XY A.19193785 O.27286523 O.34279193 http://www.streetinsider.com/PRNewswire/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that it has entered into a strategic collaboration with <span>China National Pharmaceutical Group Co., Ltd.</span> ("Sino<span id="spanHghlt16e1">pharm</span><span id="spanHghlt57e6">"</span>). The two parties will establish the Sino<span id="spanHghlt2cda">pharm</span> - Harbour BioMed <span id="spanHghlt2b84">Innova</span>tion Consortium (the "<span id="spanHghlt0fa5">Inno</span>vation Consortium") to advance collaborative research and development of innovative biologics.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html Mon, 27 Jul 2026 05:02:00 -0400 02142 2142 6XY A.19193785 O.27286523 O.34279193 http://www.streetinsider.com/PRNewswire/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that it has entered into a strategic collaboration with <span>China National Pharmaceutical Group Co., Ltd.</span> ("Sino<span id="spanHghlt16e1">pharm</span><span id="spanHghlt57e6">"</span>). The two parties will establish the Sino<span id="spanHghlt2cda">pharm</span> - Harbour BioMed <span id="spanHghlt2b84">Innova</span>tion Consortium (the "<span id="spanHghlt0fa5">Inno</span>vation Consortium") to advance collaborative research and development of innovative biologics.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html Mon, 27 Jul 2026 05:02:00 -0400 02142 2142 6XY A.19193785 O.27286523 O.34279193 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a positive profit alert for the six months ended <chron>June 30, 2026</chron> (the "Reporting Period").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html Thu, 23 Jul 2026 20:02:00 -0400 02142 2142 6XY A.06822034 A.50216916 A.50216935 A.50216981 O.20026344 O.34279193 O.57690994 O.65371608 O.77292130 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a positive profit alert for the six months ended <chron>June 30, 2026</chron> (the "Reporting Period").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html Thu, 23 Jul 2026 20:02:00 -0400 02142 2142 6XY A.06822034 A.50216916 A.50216935 A.50216981 O.20026344 O.34279193 O.57690994 O.65371608 O.77292130 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a positive profit alert for the six months ended <chron>June 30, 2026</chron> (the "Reporting Period").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html Thu, 23 Jul 2026 20:02:00 -0400 02142 2142 6XY A.06822034 A.50216916 A.50216935 A.50216981 O.20026344 O.34279193 O.57690994 O.65371608 O.77292130 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a positive profit alert for the six months ended <chron>June 30, 2026</chron> (the "Reporting Period").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html Thu, 23 Jul 2026 20:02:00 -0400 02142 2142 6XY A.06822034 A.50216916 A.50216935 A.50216981 O.20026344 O.34279193 O.57690994 O.65371608 O.77292130 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a positive profit alert for the six months ended <chron>June 30, 2026</chron> (the "Reporting Period").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html Thu, 23 Jul 2026 20:02:00 -0400 02142 2142 6XY A.06822034 A.50216916 A.50216935 A.50216981 O.20026344 O.34279193 O.57690994 O.65371608 O.77292130 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a positive profit alert for the six months ended <chron>June 30, 2026</chron> (the "Reporting Period").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html Thu, 23 Jul 2026 20:02:00 -0400 02142 2142 6XY A.06822034 A.50216916 A.50216935 A.50216981 O.20026344 O.34279193 O.57690994 O.65371608 O.77292130 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a positive profit alert for the six months ended <chron>June 30, 2026</chron> (the "Reporting Period").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html Thu, 23 Jul 2026 20:02:00 -0400 02142 2142 6XY A.06822034 A.50216916 A.50216935 A.50216981 O.20026344 O.34279193 O.57690994 O.65371608 O.77292130 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a positive profit alert for the six months ended <chron>June 30, 2026</chron> (the "Reporting Period").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html Thu, 23 Jul 2026 20:02:00 -0400 02142 2142 6XY A.06822034 A.50216916 A.50216935 A.50216981 O.20026344 O.34279193 O.57690994 O.65371608 O.77292130 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a positive profit alert for the six months ended <chron>June 30, 2026</chron> (the "Reporting Period").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html Thu, 23 Jul 2026 20:02:00 -0400 02142 2142 6XY A.06822034 A.50216916 A.50216935 A.50216981 O.20026344 O.34279193 O.57690994 O.65371608 O.77292130 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a positive profit alert for the six months ended <chron>June 30, 2026</chron> (the "Reporting Period").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html Thu, 23 Jul 2026 20:02:00 -0400 02142 2142 6XY A.06822034 A.50216916 A.50216935 A.50216981 O.20026344 O.34279193 O.57690994 O.65371608 O.77292130 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a positive profit alert for the six months ended <chron>June 30, 2026</chron> (the "Reporting Period").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html Thu, 23 Jul 2026 20:02:00 -0400 02142 2142 6XY A.06822034 A.50216916 A.50216935 A.50216981 O.20026344 O.34279193 O.57690994 O.65371608 O.77292130 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a positive profit alert for the six months ended <chron>June 30, 2026</chron> (the "Reporting Period").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html Thu, 23 Jul 2026 20:02:00 -0400 02142 2142 6XY A.06822034 A.50216916 A.50216935 A.50216981 O.20026344 O.34279193 O.57690994 O.65371608 O.77292130 http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a positive profit alert for the six months ended <chron>June 30, 2026</chron> (the "Reporting Period").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Announces+Positive+Profit+Alert+for+2026+Interim+Results%2C+Marking+Seventh+Consecutive+Profitable+Half-Year+as+Platform-Based+Advantages+Drive+Sustainable+Growth/26809383.html Thu, 23 Jul 2026 20:02:00 -0400 02142 2142 6XY A.06822034 A.50216916 A.50216935 A.50216981 O.20026344 O.34279193 O.57690994 O.65371608 O.77292130